[go: up one dir, main page]

US20160348109A1 - Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry - Google Patents

Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry Download PDF

Info

Publication number
US20160348109A1
US20160348109A1 US15/234,736 US201615234736A US2016348109A1 US 20160348109 A1 US20160348109 A1 US 20160348109A1 US 201615234736 A US201615234736 A US 201615234736A US 2016348109 A1 US2016348109 A1 US 2016348109A1
Authority
US
United States
Prior art keywords
rna
functional group
ribose rings
provides
another embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/234,736
Inventor
Daniel Zewge
Francis Gosselin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirna Therapeutics Inc
Original Assignee
Sirna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/021629 external-priority patent/WO2011090968A1/en
Application filed by Sirna Therapeutics Inc filed Critical Sirna Therapeutics Inc
Priority to US15/234,736 priority Critical patent/US20160348109A1/en
Publication of US20160348109A1 publication Critical patent/US20160348109A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/40—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the same carbon atom of the carbon skeleton, e.g. amino-ketals, ortho esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/52—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Definitions

  • RNA interference is an evolutionarily conserved cellular mechanism of post-transcriptional gene silencing found in fungi, plants and animals that uses small RNA molecules to inhibit gene expression in a sequence-specific manner.
  • the RNAi machinery can be harnessed to destruct any mRNA of a known sequence. This allows for suppression (knock-down) of any gene from which it was generated and consequently preventing the synthesis of the target protein.
  • Smaller siRNA duplexes introduced exogenously were found to be equally effective triggers of RNAi (Zamore, P. D., Tuschl, T., Sharp, P. A., Bartel, D. P. Cell 2000, 101, 25-33).
  • Synthetic RNA duplexes can be used to modulate therapeutically relevant biochemical pathways, including ones which are not accessible through traditional small molecule control.
  • RNA modification of RNA leads to improved physical and biological properties such as nuclease stability (Damha et al Drug Discovery Today 2008, 13(19/20), 842-855), reduced immune stimulation (Sioud TRENDS in Molecular Medicine 2006, 12(4), 167-176), enhanced binding (Koller, E. et al Nucl. Acids Res. 2006, 34, 4467-4476), enhanced lipophilic character to improve cellular uptake and delivery to the cytoplasm.
  • RNA modifications of RNA have relied heavily on work-intensive, cumbersome, multi-step syntheses of structurally novel nucleoside analogues and their corresponding phosphoramidites prior to RNA assembly.
  • a major emphasis has been placed on chemical modification of the 2′-position of nucleosides.
  • a rigorous approach to structure-activity-relationship (SAR) studies of chemical modifications will obviously require synthesis and evaluation of all four canonical ribonucleosides [adenosine (A), cytidine (C), uridine (U), guanosine (G)].
  • RNA Post-synthetic chemical modifications of RNA have centered for the most part on simple conjugation chemistry. Conjugation has largely been performed on either the 3′ or the 5′-end of the RNA via alkylamine and disulfide linkers. These modifications have allowed conjugation of RNA to various compounds such as cholesterol, fatty acids, poly(ethylene)glycols, various delivery vehicles and targeting agents such as poly(amines), peptides, peptidomimetics, and carbohydrates.
  • This invention relates to the post-synthetic chemical modification of RNA at the 2′-position on the ribose ring via a copper catalyzed Huisgen cycloaddition (“click” chemistry: Kolb, Sharpless Drug Discovery Today 2003, 8, 1128).
  • the invention 1) avoids complex, tedious multi-step syntheses of each desired modified ribonucleoside; 2) allows diverse chemical modifications using high-fidelity chemistry that is completely orthogonal to commonly used alkylamino, carboxylate and disulfide linker reactivities; 3) allows introduction of functional groups that are incompatible with modern automated solid-phase synthesis of RNA and subsequent cleavage-deprotection steps; 4) allows introduction of functional groups useful as targeting ligands; and 5) enables high-throughput structure-activity relationship studies on chemically modified RNA in 96-well format.
  • FIG. 1 Systematic evaluation of the impact on knockdown of the 2′-O-benzyl-triazole inosine chemical modification along positions 1 through 19 of the guide strand of a SSB(291) siRNA.
  • FIG. 2 Systematic evaluation of the impact on knockdown of the 2′-O-phenylthiomethyl-triazole inosine chemical modification along positions 1 through 19 of the guide strand of a SSB(291) siRNA.
  • FIG. 3 Systematic evaluation of the impact on knockdown of the 2′-O-benzyl-triazole inosine chemical modification was systematically evaluated along positions 1 through 19 of the guide strand of a Luc(80) siRNA.
  • FIG. 4 Systematic evaluation of the impact on knockdown of the 2′-O-phenylthiomethyl-triazole inosine chemical modification was systematically evaluated along positions 1 through 19 of the guide strand of a Luc(80) siRNA.
  • FIG. 5 Duration of knockdown activity of the 2′-O-benzyl-triazole inosine chemical modification was systematically evaluated along positions 1 through 19 of the guide strand of a Luc(80) siRNA.
  • FIG. 6 Duration of knockdown activity of the 2′-O-phenylthiomethyl inosine chemical modification was systematically evaluated along positions 1 through 19 of the guide strand of a Luc(80) siRNA.
  • FIG. 7 Introduction of N-acetyl-galactosamine as chemical modification.
  • FIG. 8 Introduction of poly(ethylene)glycol amine in SSB(291) RNA.
  • FIG. 9 Multi-click for introduction of multiple N-acetylgalactosamine chemical modifications in one synthetic operation.
  • This invention relates to the post-synthetic chemical modification of RNA at the 2′-postion on the ribose ring via a copper catalyzed Huisgen cycloaddition (“click” chemistry: Kolb, Sharpless Drug Discovery Today 2003, 8, 1128).
  • the invention 1) avoids complex, tedious multi-step syntheses of each desired modified ribonucleoside; 2) allows diverse chemical modifications using high-fidelity chemistry that is completely orthogonal to commonly used alkylamino, carboxylate and disulfide linker reactivities; 3) allows introduction of functional groups that are incompatible with modern automated solid-phase synthesis of RNA and subsequent cleavage-deprotection steps; 4) allows introduction of functional groups useful as targeting ligands; and 5) enables high-throughput structure-activity relationship studies on chemically modified RNA in 96-well format.
  • the prior art discloses the use of “click chemistry” to generate modified oligonucleotides wherein the alkyne functional group is on the phosphate backbone or the base in DNA and RNA molecules or the alkyne functional group is on the ribose of DNA molecules.
  • the modification is for labeling purposes.
  • RNA with alkyne functional group at the 2′-position is not known.
  • click chemistry to generate 2′-modified RNA wherein the alkyne functional group is on the ribose is not known.
  • RNA can undergo auto-catalytic cleavage via intramolecular cyclization of the 2′-position onto the 3′-phosphodiester. Modification of the 2′-position is critical for RNA stability and therapeutic applicability.
  • RNA with alkyne functional group at the 2′-position is critical for RNA stability and therapeutic applicability.
  • the current invention relates to chemical modification of RNA at the 2′-position of the ribose ring based on the 1,3-dipolar cycloaddition (Huisgen reaction) between alkynes and azides.
  • the 1,3-dipolar cycloaddition (Huisgen reaction) between alkynes and azides is known. (Tornoe, Christensen, Meldal J. Org. Chem. 2002, 67, 3057; Rostovstev, Green, Fokin, Sharpless Angew. Chem. Int. Ed. 2002, 41, 2596).
  • the invention provides a process for introducing 2′-modifications into RNA, said process comprises a) obtaining RNA with an alkyne functional group at the 2′-position on at least one ribose ring; b) creating a solution of RNA in a solvent;
  • the process is conducted in high-throughput format.
  • the step (a) RNA may be purchased or synthesized.
  • the step (b) solvent is selected from aqueous buffer solutions (including phosphate buffers), aqueous DMSO, CH 3 CN, DMF, DMAc, NMP and a suitable ionic liquid.
  • the step (b) solvent is aqueous DMSO.
  • the step (c) metal catalyst is selected from copper and ruthenium.
  • the step (c) metal catalyst is copper.
  • the step (c) metal catalyst is copper with a suitable ligand to stabilize the Cu(I) oxidation state.
  • the step (c) reaction is performed at temperatures between ⁇ 20-300° C. for 0 to 18 h.
  • step (c) reaction is performed at temperatures between 5-120° C. for 0.5 to 18 h.
  • the step (c) reaction is performed at temperatures between 20-100° C. for 0.5 to 18 h. In an embodiment, the step (c) reaction is performed at temperatures between 60-90° C. for 0.5 to 18 h.
  • step (c) reaction is performed at temperatures between 65-80° C. for 0.5 to 18 h.
  • the invention provides a process for introducing 2′-modifications into RNA, said process comprises a) obtaining RNA with an alkyne functional group at the 2′-position on at least one ribose ring of an internal nucleotide; b) creating a solution of RNA in a solvent; and c) adding an organic azide and a metal catalyst to the solution to form a reaction and creating a 2′-modified RNA.
  • the process is conducted in high-throughput format.
  • the step (a) RNA may be purchased or synthesized.
  • the step (b) solvent is selected from aqueous buffer solutions (including phosphate buffers), aqueous DMSO, CH 3 CN, DMF, DMAc, NMP and a suitable ionic liquid.
  • the step (b) solvent is aqueous DMSO.
  • the step (c) metal catalyst is selected from copper and ruthenium.
  • the step (c) metal catalyst is copper.
  • the step (c) metal catalyst is copper with a suitable ligand to stabilize the Cu(I) oxidation state.
  • the step (c) reaction is performed at temperatures between ⁇ 20-300° C. for 0 to 18 h.
  • step (c) reaction is performed at temperatures between 5-120° C. for 0.5 to 18 h.
  • the step (c) reaction is performed at temperatures between 20-100° C. for 0.5 to 18 h.
  • the step (c) reaction is performed at temperatures between 60-90° C. for 0.5 to 18 h. In an embodiment, the step (c) reaction is performed at temperatures between 65-80° C. for 0.5 to 18 h.
  • the invention provides a process for introducing 2′-modifications into RNA, said process comprises a) obtaining RNA with an alkyne functional group at the 2′-position on at least one ribose ring of an internal nucleotide; b) creating a solution of RNA in a solvent; c) adding an organic azide and a metal catalyst to the solution to form a reaction and creating a 2′-modified RNA; and d) purifying the 2′-modified RNA.
  • the step (a) RNA may be purchased or synthesized.
  • the step (c) solvent is selected from aqueous buffer solutions (including phosphate buffers), aqueous DMSO, CH 3 CN, DMF, DMAc, NMP and a suitable ionic liquid.
  • the step (c) solvent is aqueous DMSO.
  • the step (c) metal catalyst is selected from copper and ruthenium.
  • the step (c) metal catalyst is copper.
  • the step (c) metal catalyst is copper with a suitable ligand to stabilize Cu(I) oxidation state.
  • the step (c) reaction is performed at temperatures between ⁇ 20-300° C. for 0 to 18 h.
  • step (c) reaction is performed at temperatures between 5-120° C. for 0.5 to 18 h.
  • the step (c) reaction is performed at temperatures between 20-100° C. for 0.5 to 18 h. In an embodiment, the step (c) reaction is performed at temperatures between 60-90° C. for 0.5 to 18 h.
  • step (c) reaction is performed at temperatures between 65-80° C. for 0.5 to 18 h.
  • the step (d) purification is performed in high-throughput format on 96-well C18 cartridges (solid-phase extraction) or strong-anion-exchange-HPLC or reverse-phase HPLC or poly(acrylamide) gel electrophoresis (PAGE) or size-exclusion chromatography.
  • the invention provides a process for introducing 2′-modifications into RNA, said process comprises a) obtaining RNA with an alkyne functional group at the 2′-position on at least one ribose ring of an internal nucleotide; b) creating a solution of RNA in a solvent; c) adding an organic azide and a metal catalyst to the solution to form a reaction and creating a 2′-modified RNA; d) cooling the solution and adding a fluoride source; e) heating the solution; 0 cooling the solution and adding a diluent; and g) purifying the 2′-modified RNA.
  • the step (a) RNA may be purchased or synthesized.
  • the step (c) solvent is selected from aqueous buffer solutions (including phosphate buffers), aqueous DMSO, CH 3 CN, DMF, DMAc, NMP and a suitable ionic liquid.
  • the step (c) solvent is aqueous DMSO.
  • the step (c) metal catalyst is selected from copper and ruthenium.
  • the step (c) metal catalyst is copper.
  • the step (c) metal catalyst is copper with a suitable ligand to stabilize Cu(I) oxidation state.
  • the step (c) reaction is performed at temperatures between ⁇ 20-300° C. for 0 to 18 h. In an embodiment, the step (c) reaction is performed at temperatures between 5-120° C. for 0.5 to 18 h.
  • the step (c) reaction is performed at temperatures between 20-100° C. for 0.5 to 18 h.
  • the step (c) reaction is performed at temperatures between 60-90° C. for 0.5 to 18 h.
  • step (c) reaction is performed at temperatures between 65-80° C. for 0.5 to 18 h.
  • the step (e) fluoride source is Et 3 N ⁇ 3HF, tetrabutylammonium fluoride, potassium fluoride and ammonium fluoride.
  • the step (e) fluoride source is ammonium fluoride.
  • the step (f) diluent is NaCl.
  • the step (g) purification is performed in high-throughput format on 96-well C18 cartridges (solid-phase extraction) or strong-anion-exchange-HPLC or reverse-phase HPLC or poly(acrylamide) gel electrophoresis (PAGE) or size-exclusion chromatography.
  • the instant invention also discloses a method for attaching targeting ligands to RNA utilizing the process described herein.
  • the instant invention further discloses a method for attaching targeting ligands to internal nucleotides in RNA utilizing the process described herein.
  • the invention provides a RNA with an alkyne functional group at the 2′-position on one or more ribose rings.
  • the invention provides a RNA with an alkyne functional group at the 2′-position on two or more ribose rings.
  • the invention provides a RNA with an alkyne functional group at the 2′-position on three or more ribose rings.
  • the invention provides a RNA with an alkyne functional group at the 2′-position on four or more ribose rings.
  • the invention provides a RNA with an alkyne functional group at the 2′-position on five or more ribose rings.
  • the invention provides a RNA with an alkyne functional group at the 2′-position on six or more ribose rings.
  • the invention provides a RNA with an alkyne functional group at the 2′-position on seven or more ribose rings.
  • the invention provides a RNA with an alkyne functional group at the 2′-position on eight or more ribose rings.
  • the invention provides a RNA with an alkyne functional group at the 2′-position on nine or more ribose rings.
  • the invention provides a RNA with an alkyne functional group at the 2′-position on ten or more ribose rings.
  • the invention provides a RNA with an alkyne functional group at the 2′-position on one or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a RNA with an alkyne functional group at the 2′-position on two or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a RNA with an alkyne functional group at the 2′-position on three or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a RNA with an alkyne functional group at the 2′-position on four or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a RNA with an alkyne functional group at the 2′-position on five or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a RNA with an alkyne functional group at the 2′-position on six or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a RNA with an alkyne functional group at the 2′-position on seven or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a RNA with an alkyne functional group at the 2′-position on eight or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a RNA with an alkyne functional group at the 2′-position on nine or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a RNA with an alkyne functional group at the 2′-position on ten or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a miRNA with an alkyne functional group at the 2′-position on one or more ribose rings.
  • the invention provides a miRNA with an alkyne functional group at the 2′-position on two or more ribose rings.
  • the invention provides a miRNA with an alkyne functional group at the 2′-position on three or more ribose rings.
  • the invention provides a miRNA with an alkyne functional group at the 2′-position on four or more ribose rings.
  • the invention provides a miRNA with an alkyne functional group at the 2′-position on five or more ribose rings.
  • the invention provides a miRNA with an alkyne functional group at the 2′-position on six or more ribose rings.
  • the invention provides a miRNA with an alkyne functional group at the 2′-position on seven or more ribose rings.
  • the invention provides a miRNA with an alkyne functional group at the 2′-position on eight or more ribose rings.
  • the invention provides a miRNA with an alkyne functional group at the 2′-position on nine or more ribose rings.
  • the invention provides a miRNA with an alkyne functional group at the 2′-position on ten or more ribose rings.
  • the invention provides a miRNA with an alkyne functional group at the 2′-position on one or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a miRNA with an alkyne functional group at the 2′-position on two or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a miRNA with an alkyne functional group at the 2′-position on three or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a miRNA with an alkyne functional group at the 2′-position on four or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a miRNA with an alkyne functional group at the 2′-position on five or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a miRNA with an alkyne functional group at the 2′-position on six or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a miRNA with an alkyne functional group at the 2′-position on seven or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a miRNA with an alkyne functional group at the 2′-position on eight or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a miRNA with an alkyne functional group at the 2′-position on nine or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a miRNA with an alkyne functional group at the 2′-position on ten or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on one or more ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on two or more ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on three or more ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on four or more ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on five or more ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on six or more ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on seven or more ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on eight or more ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on nine or more ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on ten or more ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on one or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on two or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on three or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on four or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on five or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on six or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on seven or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on eight or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on nine or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on ten or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on one ribose ring.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on two ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on three ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on four ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on five ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on six ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on seven ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on eight ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on nine ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on ten ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on one ribose ring excluding the external 5′ and 3′ ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on two ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on three ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on four ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on five ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on six ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on seven ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on eight ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on nine ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides a siRNA with an alkyne functional group at the 2′-position on ten ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on one ribose ring.
  • the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on two ribose rings.
  • the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on three ribose rings.
  • the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on four ribose rings.
  • the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on five ribose rings.
  • the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on six ribose rings.
  • the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on seven ribose rings.
  • the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on eight ribose rings.
  • the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on nine ribose rings.
  • the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on ten ribose rings.
  • the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on one ribose ring excluding the external 5′ and 3′ ribose rings.
  • the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on two ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on three ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on four ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on five ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on six ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on seven ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on eight ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on nine ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on ten ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on one ribose ring.
  • the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on two ribose rings.
  • the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on three ribose rings.
  • the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on four ribose rings.
  • the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on five ribose rings.
  • the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on six ribose rings.
  • the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on seven ribose rings.
  • the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on eight ribose rings.
  • the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on nine ribose rings.
  • the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on ten ribose rings.
  • the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on one ribose ring excluding the external 5′ and 3′ ribose rings.
  • the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on two ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on three ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on four ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on five ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on six ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on seven ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on eight ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on nine ribose rings excluding the external 5′ and 3′ ribose rings.
  • the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on ten ribose rings excluding the external 5′ and 3′ ribose rings.
  • 2′-modified RNA means a RNA wherein at least one ribose ring is modified at the 2′-position.
  • Alkyne functional group means any chemical compound containing an alkyne functional group.
  • the preferred “Alkyne functional group” is the propargyl moiety shown throughout this disclosure.
  • High-throughput format means that several operations are run in parallel fashion such as for example in 96-well plate chemical synthesis, 96-well plate purification, 96-well plate chromatographic analysis and 96-well plate mass spectrometric analysis.
  • Internal nucleotide means a nucleotide in an RNA molecule that is not at the 3′- or 5′-end.
  • the internal nucleotides in a 21mer siRNA occur at positions 2-20.
  • RNA means a chemically modified or unmodified ribonucleic acid molecule (single stranded or double stranded) comprising at least 3 nucleotides, including but not limited to miRNA and siRNA. In another embodiment, “RNA” means miRNA. In another embodiment, “RNA” means siRNA. Chemical modifications include, for example, modifications to the base, ribose ring (excluding modifications to the 2′-position), and phosphate backbone. The base can be a canonical base (A, G, T and U) or a modified or universal base (including but not limited to inosine and nitroindole).
  • Organic azide means any chemical compound containing the azide functional group.
  • Metal catalyst means any chemical form of copper and ruthenium, including solid-supported variants.
  • metal catalyst include CuBr, CuBr ⁇ Me 2 S, CuI, CuSO 4 or CuOAc and a suitable reducing agent such as sodium ascorbate, Cu(CH 3 CN) 4 PF 6 , CpRuCl(PPh 3 ) 2 , and Cp*RuCl(PPh 3 ) 2 .
  • Ribose ring means the ribose moiety in a ribonucleotide.
  • Targeting ligand means a conjugate delivery moiety capable of delivering an oligonucleotide to a target cell of interest.
  • Targeting ligands include, but are not limited to, lipids (cholesterol), sugars (NAG), proteins (transferrin), peptides, poly(ethylene)glycols and antibodies. See Juliano et al., Nucleic Acids Research, 2008, 1-14, doi:10.1093/nar/gkn342.
  • the present invention provides a process for introducing chemical modifications into RNA at the 2′-position on the ribose ring. It is well known in the art that RNA are useful for therapeutic and research purposes.
  • RNA The synthesis of RNA is well known in the art.
  • a suitable 2′-O-propargyl nucleoside phosphoramidite is incorporated into RNA using modern techniques based on the phosphoramidite approach.
  • the crude, solid-support bound protected oligonucleotide is then treated with aqueous methylamine to remove nucleobase and phosphate protecting groups.
  • the crude product is then lyophilized to remove volatiles.
  • the crude product is dissolved in DMSO:H 2 O, treated with a suitable organic azide and a copper catalyst. After aging an appropriate amount of time, the reaction mixture is treated with fluoride to remove the 2′-O-tent-butyldimethylsilyl protecting groups.
  • the crude product is then purified to obtain the chemically modified RNA.
  • RNA Lyophilized crude RNA ( ⁇ 50 nmol) containing at least one alkyne functional group (shown below) in 96-well format was dissolved in DMSO:water (75:25, 40 ⁇ L). Benzyl azide (1M in DMSO, 40 ⁇ L) was added, followed by a freshly prepared solution of CuBr ⁇ Me 2 S in DMSO (12 mM, 40 ⁇ L). The reaction block was sealed and heated at 65-80° C. overnight. The solution was cooled to room temperature and ammonium fluoride (100 ⁇ L, 5.4M in water) was added. The solution was heated at 65° C. for 1 h, cooled to room temperature and diluted with 1M aqueous NaCl (800 ⁇ L). The crude product was purified on a C18 cartridge to afford the desired chemically modified benzyl-triazole-linked RNA as determined by HPLC and LC-MS analyses.
  • RNA ( ⁇ 50 nmol) containing at least one alkyne functional group (shown below) was dissolved in DMSO:water (75:25, 40 ⁇ L). Azidomethyl phenyl sulfide (1M in DMSO, 40 ⁇ L) was added, followed by a freshly prepared solution of CuBr ⁇ Me 2 S in DMSO (12 mM, 40 ⁇ L). The reaction block was sealed and heated to 65-80° C. overnight. The solution was cooled to room temperature and ammonium fluoride (100 ⁇ L, 5.4M in water) was added. The solution was heated at 65° C. for 1 h, cooled to room temperature and diluted with 1M aqueous NaCl (800 ⁇ L). The crude product was purified on a C18 cartridge to afford the desired chemically modified phenylthiomethyl-triazole-linked RNA as determined by HPLC and LC-MS analyses.
  • RNA ( ⁇ 50 nmol) containing at least one alkyne functional group (shown below) was dissolved in DMSO:water (75:25, 40 ⁇ L). Ethyl azidoacetate (1M in DMSO, 40 ⁇ L) was added, followed by a freshly prepared solution of CuBr ⁇ Me 2 S in DMSO (12 mM, 40 ⁇ L). The reaction block was sealed and heated to 65-80° C. overnight. The solution was cooled to room temperature and ammonium fluoride (100 ⁇ L, 5.4M in water) was added. The solution was heated at 65° C. for 1 h, cooled to room temperature and diluted with 1M aqueous NaCl (800 ⁇ L). The crude product was purified on a C18 cartridge to afford the desired chemically modified ethyl-carboxymethyl-1,4-triazole-linked RNA as determined by HPLC and LC-MS analyses.
  • RNA ( ⁇ 50 nmol) containing at least one alkyne functional group (shown below) was dissolved in DMSO:water (75:25, 40 ⁇ L). Modified N-acetyl galactosamine azide (1M in DMSO, 40 ⁇ L) was added, followed by a freshly prepared solution of CuBr ⁇ Me 2 S in DMSO (12 mM, 40 ⁇ L). The reaction block was sealed and heated to 65-80° C. overnight. The solution was cooled to room temperature and ammonium fluoride (100 ⁇ L, 5.4M in water) was added. The solution was heated at 65° C. for 1 h, cooled to room temperature and diluted with 1M aqueous NaCl (800 ⁇ L). The crude product was purified on a C18 cartridge to afford the desired chemically modified N-acetylgalactosamine-1,4-triazole-linked RNA as determined by HPLC and LC-MS analyses.
  • RNA ( ⁇ 50 nmol) containing more than one alkyne functional group (shown below) was dissolved in DMSO:water (75:25, 40 ⁇ L). Modified N-acetylgalactosamine azide (1M in DMSO, 40 ⁇ L) was added, followed by a freshly prepared solution of CuBr ⁇ Me 2 S in DMSO (12 mM, 40 ⁇ L). The reaction block was sealed and heated to 65-80° C. overnight. The solution was cooled to room temperature and ammonium fluoride (100 ⁇ L, 5.4M in water) was added. The solution was heated at 65° C. for 1 h, cooled to room temperature and diluted with 1M aqueous NaCl (800 ⁇ L). The crude product was purified on a C18 cartridge to afford the desired chemically modified N-acetylgalactosamine-1,4-triazole-linked RNA as determined by HPLC and LC-MS analyses.
  • RNA 50 nmol containing at least one alkyne functional group (shown below) was dissolved in DMSO:water (75:25, 40 uL). Benzyl azide (1M in DMSO, 40 uL) was added, followed by a freshly prepared solution of CuBr ⁇ Me 2 S in DMSO (12 mM, 40 uL). The reaction block was sealed and heated at 65-80° C. overnight. The solution was cooled to room temperature and ammonium fluoride (100 ⁇ L, 5.4M in water) was added. The solution was heated at 65° C. for 1 h, cooled to room temperature and diluted with 1M aqueous NaCl (800 uL). The crude product was purified on a C18 cartridge to afford the desired chemically modified benzyl-1,4-triazole-linked RNA as determined by HPLC and LC-MS analyses.
  • RNA 50 nmol containing at least one alkyne functional group (shown below) was dissolved in DMSO:water (75:25, 40 uL). 11-Azido-3,6,9-trioxaundecan-1-amine (1M in DMSO, 40 uL) was added, followed by a freshly prepared solution of CuBr ⁇ Me 2 S in DMSO (12 mM, 40 uL). The reaction block was sealed and heated at 65-80° C. overnight. The solution was cooled to room temperature and ammonium fluoride (100 ⁇ L, 5.4M in water) was added. The solution was heated at 65° C.
  • RNA oligomers with the first nucleotide, uridine (U), replaced with 2′-O-propargyl-inosine. Then, a second sequence, in which the second nucleoside (U) was replaced with 2′-O-propargyl-inosine was synthesized, keeping all other nucleotides unchanged.
  • Hepal-6 cells were transfected with 10 nM of either the unmodified, modified, or negative control siRNA using a commercial lipid transfection reagent.
  • the target mRNA was assessed for degradation using standard Taqman procedures.
  • Multiplex luciferase assay for in vitro duration study is modified from the manufacturer's instruction using HeLa-luc cell line. Briefly, the cell viability and the luciferease expression at the same well are determined by CellTiter-FluorTM (Promega, Cat# G6082) and Bright-GloTM (Promega Cat# E2620) sequentially.
  • HeLa-luc cell line is a stable firefly luciferase reporter expression cell line.
  • Bright-GloTM luciferase assay system contains the stable substrate—luciferin and assay buffer.
  • the luminescent reaction of luciferease and luciferin has high quantum yield and can be detected as luminescence intensity, which represents the luciferase expression level.
  • Target siRNAs containing luciferase coding region is designed to be transfected into the HeLa-luc cells. Once the taget is effected, the luciferase expression is reduced accordingly, Therefore, the siRNA silencing efficacy can be determined by the relative luminecence intensity of treated cells.
  • CellTiter-fluor kit measures the conserved and constitutive protease activity within live cells and therefore serves as a marker of cell viability, using a fluorogenic, cell-permeable peptide substrate (glycyl-phenylalanyl-aminofluorocoumarin; GF-AFC).
  • Luciferase stable expressed HeLa-luc cell cells are plated in 96-well plates at density of 4,500 cells per well in 100 ⁇ L DMEM media without antibiotics 24 hours prior to transfection.
  • siRNA transfection is performed using the RNAiMAXTM (Invitrogen). Briefly, 0.05 ⁇ M siRNA are mixed with Opti-MEMmedia and RNAiMAX and incubated at room temperature for 15 min. The mix is then added to the cells. The final siRNA concentration is 1 nM. Cell plates for all time points are transfected at same time with a medium change at 6 hours post-transfection into 100 ⁇ L of fresh completed DMEM (DMEM+10% FBS+Pen/strep).
  • In vitro duration is determined by the luciferase expression post-transfection at four time points: day 1, day 2, day 5 and day 7. Addition medium changes are performed at day 2 and day 5 into 100 ⁇ L of fresh completed DMEM (DMEM+10% FBS+Penn/strep). Luciferase levels are determined using the Bright-Glo Luminescence Assay (Promega) and measuring the wells on an Envison instrument (Perkin Elmer) according to manufacturer's instructions.
  • the cell viability of the same treatment wells is measured using CellTiter-fluor kit (Promega) according to manufacturer's instructions.
  • This assay measures the conserved and constitutive protease activity within live cells and therefore servers as a marker of cell viability, using a fluorogenic, cell-permeable peptide substrate (glycyl-phenylalanyl-aminofluorocoumarin; GF-AFC).
  • the fluorescence was measured on the Envision using exciton filter at 405 nm and emission filter at 510 nm.
  • the luciferase expression was normalized to cell viability. The log of this number was calculated to determine the luciferase protein that was degraded (knockdown). A non-targeting siRNA was subtracted from this value to account for non-specific background.
  • RNAs made by the process of the invention are useful in high-throughput structure-activity relationship studies on chemically modified RNA in 96-well format.
  • FIG. 1 the impact on knockdown of the 2′-O-benzyl-triazole inosine chemical modification was systematically evaluated along positions 1 through 19 of the guide strand of an siRNA targeting mRNA SSB(291).
  • poly(ethylene)glycol amines can be introduced to improve solubility properties, cellular uptake, immune stealth, reduce metabolic clearance and delivery of RNA.
  • the “click” reaction can be utilized to introduce multiple chemical modifications in one synthetic operation.
  • the click reaction was performed to introduce three units of protected N-acetylgalactosamine on RNA. This may lead to improved physical properties towards solubility, cellular uptake, and delivery of siRNA.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

This invention relates to a 2′-modified RNA agent comprising at least one RNA strand containing a 2′-O substituent having an alkyne functional group attaching to the O atom at the 2′-position on one or more ribose rings, wherein the 2′-O substituent is located at one or more of positions 2, 3, 4, 7, 8, 9, 10, 11, 13, 14, and 16, from 5′-end of the RNA strand. This invention also relates to a 2′-modified RNA agent comprising at least one RNA strand containing a 2′-O substituent having a triazole functional group attaching to the O atom at the 2′-position on one or more ribose rings, wherein the 2′-O substituent is located at one or more of positions 2, 3, 4, 7, 8, 9, 10, 11, 13, 14, and 16, from 5′-end of the RNA strand.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation application of U.S. patent application Ser. No. 14/609,118, filed Jan. 29, 2015, which is a continuation application of U.S. patent application Ser. No. 13/574,136, filed Jul. 19, 2012, which is a national stage application of PCT Application No. PCT/US2011/021629, filed Jan. 19, 2011, which claims the benefit of priority to U.S. Provisional Patent Application No. 61/297,377, filed Jan. 22, 2010, and U.S. Provisional Application No. 61/325,908, filed Apr. 20, 2010; all of which are incorporated by reference herein in their entirety.
    • BACKGROUND OF THE INVENTION
  • RNA interference (RNAi) is an evolutionarily conserved cellular mechanism of post-transcriptional gene silencing found in fungi, plants and animals that uses small RNA molecules to inhibit gene expression in a sequence-specific manner. The RNAi machinery can be harnessed to destruct any mRNA of a known sequence. This allows for suppression (knock-down) of any gene from which it was generated and consequently preventing the synthesis of the target protein. Smaller siRNA duplexes introduced exogenously were found to be equally effective triggers of RNAi (Zamore, P. D., Tuschl, T., Sharp, P. A., Bartel, D. P. Cell 2000, 101, 25-33). Synthetic RNA duplexes can be used to modulate therapeutically relevant biochemical pathways, including ones which are not accessible through traditional small molecule control.
  • Chemical modification of RNA leads to improved physical and biological properties such as nuclease stability (Damha et al Drug Discovery Today 2008, 13(19/20), 842-855), reduced immune stimulation (Sioud TRENDS in Molecular Medicine 2006, 12(4), 167-176), enhanced binding (Koller, E. et al Nucl. Acids Res. 2006, 34, 4467-4476), enhanced lipophilic character to improve cellular uptake and delivery to the cytoplasm.
  • Chemical modifications of RNA have relied heavily on work-intensive, cumbersome, multi-step syntheses of structurally novel nucleoside analogues and their corresponding phosphoramidites prior to RNA assembly. In particular, a major emphasis has been placed on chemical modification of the 2′-position of nucleosides. A rigorous approach to structure-activity-relationship (SAR) studies of chemical modifications will obviously require synthesis and evaluation of all four canonical ribonucleosides [adenosine (A), cytidine (C), uridine (U), guanosine (G)]. Furthermore, some chemical modifications bear sensitive functional groups that may be incompatible with state-of-the-art automated synthesis of RNA as well as subsequent downstream cleavage-deprotection steps. These attributes have made chemical modification of RNA prior to synthesis rather low-throughput and limited in scope.
  • Post-synthetic chemical modifications of RNA have centered for the most part on simple conjugation chemistry. Conjugation has largely been performed on either the 3′ or the 5′-end of the RNA via alkylamine and disulfide linkers. These modifications have allowed conjugation of RNA to various compounds such as cholesterol, fatty acids, poly(ethylene)glycols, various delivery vehicles and targeting agents such as poly(amines), peptides, peptidomimetics, and carbohydrates.
  • This invention relates to the post-synthetic chemical modification of RNA at the 2′-position on the ribose ring via a copper catalyzed Huisgen cycloaddition (“click” chemistry: Kolb, Sharpless Drug Discovery Today 2003, 8, 1128). The invention 1) avoids complex, tedious multi-step syntheses of each desired modified ribonucleoside; 2) allows diverse chemical modifications using high-fidelity chemistry that is completely orthogonal to commonly used alkylamino, carboxylate and disulfide linker reactivities; 3) allows introduction of functional groups that are incompatible with modern automated solid-phase synthesis of RNA and subsequent cleavage-deprotection steps; 4) allows introduction of functional groups useful as targeting ligands; and 5) enables high-throughput structure-activity relationship studies on chemically modified RNA in 96-well format.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1. Systematic evaluation of the impact on knockdown of the 2′-O-benzyl-triazole inosine chemical modification along positions 1 through 19 of the guide strand of a SSB(291) siRNA.
  • FIG. 2. Systematic evaluation of the impact on knockdown of the 2′-O-phenylthiomethyl-triazole inosine chemical modification along positions 1 through 19 of the guide strand of a SSB(291) siRNA.
  • FIG. 3. Systematic evaluation of the impact on knockdown of the 2′-O-benzyl-triazole inosine chemical modification was systematically evaluated along positions 1 through 19 of the guide strand of a Luc(80) siRNA.
  • FIG. 4. Systematic evaluation of the impact on knockdown of the 2′-O-phenylthiomethyl-triazole inosine chemical modification was systematically evaluated along positions 1 through 19 of the guide strand of a Luc(80) siRNA.
  • FIG. 5. Duration of knockdown activity of the 2′-O-benzyl-triazole inosine chemical modification was systematically evaluated along positions 1 through 19 of the guide strand of a Luc(80) siRNA.
  • FIG. 6. Duration of knockdown activity of the 2′-O-phenylthiomethyl inosine chemical modification was systematically evaluated along positions 1 through 19 of the guide strand of a Luc(80) siRNA.
  • FIG. 7. Introduction of N-acetyl-galactosamine as chemical modification.
  • FIG. 8. Introduction of poly(ethylene)glycol amine in SSB(291) RNA.
  • FIG. 9. Multi-click for introduction of multiple N-acetylgalactosamine chemical modifications in one synthetic operation.
    •  SUMMARY OF THE INVENTION
  • This invention relates to the post-synthetic chemical modification of RNA at the 2′-postion on the ribose ring via a copper catalyzed Huisgen cycloaddition (“click” chemistry: Kolb, Sharpless Drug Discovery Today 2003, 8, 1128). The invention 1) avoids complex, tedious multi-step syntheses of each desired modified ribonucleoside; 2) allows diverse chemical modifications using high-fidelity chemistry that is completely orthogonal to commonly used alkylamino, carboxylate and disulfide linker reactivities; 3) allows introduction of functional groups that are incompatible with modern automated solid-phase synthesis of RNA and subsequent cleavage-deprotection steps; 4) allows introduction of functional groups useful as targeting ligands; and 5) enables high-throughput structure-activity relationship studies on chemically modified RNA in 96-well format.
    • DETAILED DESCRIPTION OF THE INVENTION
  • Methods for the synthesis of nucleotide derivatives wherein molecules of interest are grafted on the oligonucleotide with the help of a “click chemistry” reaction between an azide function on the molecule of interest and an alkyne function on the oligonucleotide are demonstrated in U.S. 2009/0124571. This work discloses molecules such as carbohydrates, peptides, lipids, oligonucleotides, biotin, ferrocenyl compounds and fluorescent tags which are grafted onto oligonucleotides utilizing alkyne phosphoester derivatives of the oligonucleotides to make the 1,3-cycloaddition with an azide-substituted molecule of interest.
  • Methods for forming azido-modified nucleic acid conjugates of reporter molecules, carrier molecules or solid support utilizing “click chemistry” are disclosed in U.S. 2008/0050731.
  • Synthesis of modified RNA and DNA utilizing an alkyne handle on a base and subsequent “click chemistry” is disclosed in WO 2008/052775 and in CN 101550175.
  • Recent reviews regarding “click chemistry” and oligonucleotide synthesis are covered by Gramlich et al. Angew. Chem. Int. Ed. 2008, 47, 8350-8358; Amblard et al. Chem. Rev. 2009, 109, 4207-4220.
  • Thus the prior art discloses the use of “click chemistry” to generate modified oligonucleotides wherein the alkyne functional group is on the phosphate backbone or the base in DNA and RNA molecules or the alkyne functional group is on the ribose of DNA molecules. Typically, the modification is for labeling purposes.
  • The use of “click chemistry” to generate 2′-modified RNA wherein the alkyne functional group is on the ribose is not known. There are considerable differences in the physico-chemical properties of RNA and DNA. For example, it is well recognized that RNA is much less stable than DNA towards hydrolysis. Furthermore, RNA can undergo auto-catalytic cleavage via intramolecular cyclization of the 2′-position onto the 3′-phosphodiester. Modification of the 2′-position is critical for RNA stability and therapeutic applicability. RNA with alkyne functional group at the 2′-position.
  • Figure US20160348109A1-20161201-C00001
  • The current invention relates to chemical modification of RNA at the 2′-position of the ribose ring based on the 1,3-dipolar cycloaddition (Huisgen reaction) between alkynes and azides. The 1,3-dipolar cycloaddition (Huisgen reaction) between alkynes and azides is known. (Tornoe, Christensen, Meldal J. Org. Chem. 2002, 67, 3057; Rostovstev, Green, Fokin, Sharpless Angew. Chem. Int. Ed. 2002, 41, 2596).
  • In an embodiment, the invention provides a process for introducing 2′-modifications into RNA, said process comprises a) obtaining RNA with an alkyne functional group at the 2′-position on at least one ribose ring; b) creating a solution of RNA in a solvent;
  • and c) adding an organic azide and a metal catalyst to the solution to form a reaction and creating a 2′-modified RNA.
  • In an embodiment, the process is conducted in high-throughput format.
  • In an embodiment, the step (a) RNA may be purchased or synthesized.
  • In an embodiment, the step (b) solvent is selected from aqueous buffer solutions (including phosphate buffers), aqueous DMSO, CH3CN, DMF, DMAc, NMP and a suitable ionic liquid.
  • In an embodiment, the step (b) solvent is aqueous DMSO.
  • In an embodiment, the step (c) metal catalyst is selected from copper and ruthenium.
  • In an embodiment, the step (c) metal catalyst is copper.
  • In an embodiment, the step (c) metal catalyst is copper with a suitable ligand to stabilize the Cu(I) oxidation state.
  • In an embodiment, the step (c) reaction is performed at temperatures between −20-300° C. for 0 to 18 h.
  • In an embodiment, the step (c) reaction is performed at temperatures between 5-120° C. for 0.5 to 18 h.
  • In an embodiment, the step (c) reaction is performed at temperatures between 20-100° C. for 0.5 to 18 h. In an embodiment, the step (c) reaction is performed at temperatures between 60-90° C. for 0.5 to 18 h.
  • In an embodiment, the step (c) reaction is performed at temperatures between 65-80° C. for 0.5 to 18 h.
  • In another embodiment, the invention provides a process for introducing 2′-modifications into RNA, said process comprises a) obtaining RNA with an alkyne functional group at the 2′-position on at least one ribose ring of an internal nucleotide; b) creating a solution of RNA in a solvent; and c) adding an organic azide and a metal catalyst to the solution to form a reaction and creating a 2′-modified RNA.
  • In an embodiment, the process is conducted in high-throughput format.
  • In an embodiment, the step (a) RNA may be purchased or synthesized.
  • In an embodiment, the step (b) solvent is selected from aqueous buffer solutions (including phosphate buffers), aqueous DMSO, CH3CN, DMF, DMAc, NMP and a suitable ionic liquid.
  • In an embodiment, the step (b) solvent is aqueous DMSO.
  • In an embodiment, the step (c) metal catalyst is selected from copper and ruthenium.
  • In an embodiment, the step (c) metal catalyst is copper.
  • In an embodiment, the step (c) metal catalyst is copper with a suitable ligand to stabilize the Cu(I) oxidation state.
  • In an embodiment, the step (c) reaction is performed at temperatures between −20-300° C. for 0 to 18 h.
  • In an embodiment, the step (c) reaction is performed at temperatures between 5-120° C. for 0.5 to 18 h.
  • In an embodiment, the step (c) reaction is performed at temperatures between 20-100° C. for 0.5 to 18 h.
  • In an embodiment, the step (c) reaction is performed at temperatures between 60-90° C. for 0.5 to 18 h. In an embodiment, the step (c) reaction is performed at temperatures between 65-80° C. for 0.5 to 18 h.
  • In another embodiment, the invention provides a process for introducing 2′-modifications into RNA, said process comprises a) obtaining RNA with an alkyne functional group at the 2′-position on at least one ribose ring of an internal nucleotide; b) creating a solution of RNA in a solvent; c) adding an organic azide and a metal catalyst to the solution to form a reaction and creating a 2′-modified RNA; and d) purifying the 2′-modified RNA.
  • In an embodiment, the step (a) RNA may be purchased or synthesized.
  • In an embodiment, the step (c) solvent is selected from aqueous buffer solutions (including phosphate buffers), aqueous DMSO, CH3CN, DMF, DMAc, NMP and a suitable ionic liquid.
  • In an embodiment, the step (c) solvent is aqueous DMSO.
  • In an embodiment, the step (c) metal catalyst is selected from copper and ruthenium.
  • In an embodiment, the step (c) metal catalyst is copper.
  • In an embodiment, the step (c) metal catalyst is copper with a suitable ligand to stabilize Cu(I) oxidation state.
  • In an embodiment, the step (c) reaction is performed at temperatures between −20-300° C. for 0 to 18 h.
  • In an embodiment, the step (c) reaction is performed at temperatures between 5-120° C. for 0.5 to 18 h.
  • In an embodiment, the step (c) reaction is performed at temperatures between 20-100° C. for 0.5 to 18 h. In an embodiment, the step (c) reaction is performed at temperatures between 60-90° C. for 0.5 to 18 h.
  • In an embodiment, the step (c) reaction is performed at temperatures between 65-80° C. for 0.5 to 18 h.
  • In an embodiment, the step (d) purification is performed in high-throughput format on 96-well C18 cartridges (solid-phase extraction) or strong-anion-exchange-HPLC or reverse-phase HPLC or poly(acrylamide) gel electrophoresis (PAGE) or size-exclusion chromatography.
  • In another embodiment, the invention provides a process for introducing 2′-modifications into RNA, said process comprises a) obtaining RNA with an alkyne functional group at the 2′-position on at least one ribose ring of an internal nucleotide; b) creating a solution of RNA in a solvent; c) adding an organic azide and a metal catalyst to the solution to form a reaction and creating a 2′-modified RNA; d) cooling the solution and adding a fluoride source; e) heating the solution; 0 cooling the solution and adding a diluent; and g) purifying the 2′-modified RNA.
  • In an embodiment, the step (a) RNA may be purchased or synthesized.
  • In an embodiment, the step (c) solvent is selected from aqueous buffer solutions (including phosphate buffers), aqueous DMSO, CH3CN, DMF, DMAc, NMP and a suitable ionic liquid.
  • In an embodiment, the step (c) solvent is aqueous DMSO.
  • In an embodiment, the step (c) metal catalyst is selected from copper and ruthenium.
  • In an embodiment, the step (c) metal catalyst is copper.
  • In an embodiment, the step (c) metal catalyst is copper with a suitable ligand to stabilize Cu(I) oxidation state.
  • In an embodiment, the step (c) reaction is performed at temperatures between −20-300° C. for 0 to 18 h. In an embodiment, the step (c) reaction is performed at temperatures between 5-120° C. for 0.5 to 18 h.
  • In an embodiment, the step (c) reaction is performed at temperatures between 20-100° C. for 0.5 to 18 h.
  • In an embodiment, the step (c) reaction is performed at temperatures between 60-90° C. for 0.5 to 18 h.
  • In an embodiment, the step (c) reaction is performed at temperatures between 65-80° C. for 0.5 to 18 h.
  • In an embodiment, the step (e) fluoride source is Et3N·3HF, tetrabutylammonium fluoride, potassium fluoride and ammonium fluoride.
  • In an embodiment, the step (e) fluoride source is ammonium fluoride.
  • In an embodiment, the step (f) diluent is NaCl.
  • In an embodiment, the step (g) purification is performed in high-throughput format on 96-well C18 cartridges (solid-phase extraction) or strong-anion-exchange-HPLC or reverse-phase HPLC or poly(acrylamide) gel electrophoresis (PAGE) or size-exclusion chromatography.
  • In another embodiment, the instant invention also discloses a method for attaching targeting ligands to RNA utilizing the process described herein.
  • In another embodiment, the instant invention further discloses a method for attaching targeting ligands to internal nucleotides in RNA utilizing the process described herein.
  • In an embodiment, the invention provides a RNA with an alkyne functional group at the 2′-position on one or more ribose rings.
  • In another embodiment, the invention provides a RNA with an alkyne functional group at the 2′-position on two or more ribose rings.
  • In another embodiment, the invention provides a RNA with an alkyne functional group at the 2′-position on three or more ribose rings.
  • In another embodiment, the invention provides a RNA with an alkyne functional group at the 2′-position on four or more ribose rings.
  • In another embodiment, the invention provides a RNA with an alkyne functional group at the 2′-position on five or more ribose rings.
  • In another embodiment, the invention provides a RNA with an alkyne functional group at the 2′-position on six or more ribose rings.
  • In another embodiment, the invention provides a RNA with an alkyne functional group at the 2′-position on seven or more ribose rings.
  • In another embodiment, the invention provides a RNA with an alkyne functional group at the 2′-position on eight or more ribose rings.
  • In another embodiment, the invention provides a RNA with an alkyne functional group at the 2′-position on nine or more ribose rings.
  • In another embodiment, the invention provides a RNA with an alkyne functional group at the 2′-position on ten or more ribose rings.
  • In an embodiment, the invention provides a RNA with an alkyne functional group at the 2′-position on one or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a RNA with an alkyne functional group at the 2′-position on two or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a RNA with an alkyne functional group at the 2′-position on three or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a RNA with an alkyne functional group at the 2′-position on four or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a RNA with an alkyne functional group at the 2′-position on five or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a RNA with an alkyne functional group at the 2′-position on six or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a RNA with an alkyne functional group at the 2′-position on seven or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a RNA with an alkyne functional group at the 2′-position on eight or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a RNA with an alkyne functional group at the 2′-position on nine or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a RNA with an alkyne functional group at the 2′-position on ten or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In an embodiment, the invention provides a miRNA with an alkyne functional group at the 2′-position on one or more ribose rings.
  • In another embodiment, the invention provides a miRNA with an alkyne functional group at the 2′-position on two or more ribose rings.
  • In another embodiment, the invention provides a miRNA with an alkyne functional group at the 2′-position on three or more ribose rings.
  • In another embodiment, the invention provides a miRNA with an alkyne functional group at the 2′-position on four or more ribose rings.
  • In another embodiment, the invention provides a miRNA with an alkyne functional group at the 2′-position on five or more ribose rings.
  • In another embodiment, the invention provides a miRNA with an alkyne functional group at the 2′-position on six or more ribose rings.
  • In another embodiment, the invention provides a miRNA with an alkyne functional group at the 2′-position on seven or more ribose rings.
  • In another embodiment, the invention provides a miRNA with an alkyne functional group at the 2′-position on eight or more ribose rings.
  • In another embodiment, the invention provides a miRNA with an alkyne functional group at the 2′-position on nine or more ribose rings.
  • In another embodiment, the invention provides a miRNA with an alkyne functional group at the 2′-position on ten or more ribose rings.
  • In an embodiment, the invention provides a miRNA with an alkyne functional group at the 2′-position on one or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a miRNA with an alkyne functional group at the 2′-position on two or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a miRNA with an alkyne functional group at the 2′-position on three or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a miRNA with an alkyne functional group at the 2′-position on four or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a miRNA with an alkyne functional group at the 2′-position on five or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a miRNA with an alkyne functional group at the 2′-position on six or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a miRNA with an alkyne functional group at the 2′-position on seven or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a miRNA with an alkyne functional group at the 2′-position on eight or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a miRNA with an alkyne functional group at the 2′-position on nine or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a miRNA with an alkyne functional group at the 2′-position on ten or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In an embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on one or more ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on two or more ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on three or more ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on four or more ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on five or more ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on six or more ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on seven or more ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on eight or more ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on nine or more ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on ten or more ribose rings.
  • In an embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on one or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on two or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on three or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on four or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on five or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on six or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on seven or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on eight or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on nine or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on ten or more ribose rings excluding the external 5′ and 3′ ribose rings.
  • In an embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on one ribose ring.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on two ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on three ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on four ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on five ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on six ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on seven ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on eight ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on nine ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on ten ribose rings.
  • In an embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on one ribose ring excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on two ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on three ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on four ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on five ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on six ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on seven ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on eight ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on nine ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides a siRNA with an alkyne functional group at the 2′-position on ten ribose rings excluding the external 5′ and 3′ ribose rings.
  • In an embodiment, the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on one ribose ring.
  • In another embodiment, the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on two ribose rings.
  • In another embodiment, the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on three ribose rings.
  • In another embodiment, the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on four ribose rings.
  • In another embodiment, the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on five ribose rings.
  • In another embodiment, the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on six ribose rings.
  • In another embodiment, the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on seven ribose rings.
  • In another embodiment, the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on eight ribose rings.
  • In another embodiment, the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on nine ribose rings.
  • In another embodiment, the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on ten ribose rings.
  • In an embodiment, the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on one ribose ring excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on two ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on three ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on four ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on five ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on six ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on seven ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on eight ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on nine ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides the guide strand of the siRNA with an alkyne functional group at the 2′-position on ten ribose rings excluding the external 5′ and 3′ ribose rings.
  • In an embodiment, the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on one ribose ring.
  • In another embodiment, the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on two ribose rings.
  • In another embodiment, the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on three ribose rings.
  • In another embodiment, the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on four ribose rings.
  • In another embodiment, the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on five ribose rings.
  • In another embodiment, the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on six ribose rings.
  • In another embodiment, the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on seven ribose rings.
  • In another embodiment, the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on eight ribose rings.
  • In another embodiment, the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on nine ribose rings.
  • In another embodiment, the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on ten ribose rings.
  • In an embodiment, the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on one ribose ring excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on two ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on three ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on four ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on five ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on six ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on seven ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on eight ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on nine ribose rings excluding the external 5′ and 3′ ribose rings.
  • In another embodiment, the invention provides the passenger strand of the siRNA with an alkyne functional group at the 2′-position on ten ribose rings excluding the external 5′ and 3′ ribose rings.
    • Definitions
  • “2′-modified RNA” means a RNA wherein at least one ribose ring is modified at the 2′-position.
  • “Alkyne functional group” means any chemical compound containing an alkyne functional group. The preferred “Alkyne functional group” is the propargyl moiety shown throughout this disclosure.
  • “High-throughput format” means that several operations are run in parallel fashion such as for example in 96-well plate chemical synthesis, 96-well plate purification, 96-well plate chromatographic analysis and 96-well plate mass spectrometric analysis.
  • “Internal nucleotide” means a nucleotide in an RNA molecule that is not at the 3′- or 5′-end. For example, the internal nucleotides in a 21mer siRNA occur at positions 2-20.
  • “RNA” means a chemically modified or unmodified ribonucleic acid molecule (single stranded or double stranded) comprising at least 3 nucleotides, including but not limited to miRNA and siRNA. In another embodiment, “RNA” means miRNA. In another embodiment, “RNA” means siRNA. Chemical modifications include, for example, modifications to the base, ribose ring (excluding modifications to the 2′-position), and phosphate backbone. The base can be a canonical base (A, G, T and U) or a modified or universal base (including but not limited to inosine and nitroindole).
  • “Organic azide” means any chemical compound containing the azide functional group.
  • “Metal catalyst” means any chemical form of copper and ruthenium, including solid-supported variants. Examples of metal catalyst include CuBr, CuBr·Me2S, CuI, CuSO4 or CuOAc and a suitable reducing agent such as sodium ascorbate, Cu(CH3CN)4PF6, CpRuCl(PPh3)2, and Cp*RuCl(PPh3)2.
  • “Ribose ring” means the ribose moiety in a ribonucleotide.
  • “Targeting ligand” means a conjugate delivery moiety capable of delivering an oligonucleotide to a target cell of interest. Targeting ligands include, but are not limited to, lipids (cholesterol), sugars (NAG), proteins (transferrin), peptides, poly(ethylene)glycols and antibodies. See Juliano et al., Nucleic Acids Research, 2008, 1-14, doi:10.1093/nar/gkn342.
    • Utility
  • The present invention provides a process for introducing chemical modifications into RNA at the 2′-position on the ribose ring. It is well known in the art that RNA are useful for therapeutic and research purposes.
    • RNA Synthesis
  • The synthesis of RNA is well known in the art.
    • General Working Example “Click Reaction”
  • A suitable 2′-O-propargyl nucleoside phosphoramidite is incorporated into RNA using modern techniques based on the phosphoramidite approach. The crude, solid-support bound protected oligonucleotide is then treated with aqueous methylamine to remove nucleobase and phosphate protecting groups. The crude product is then lyophilized to remove volatiles. The crude product is dissolved in DMSO:H2O, treated with a suitable organic azide and a copper catalyst. After aging an appropriate amount of time, the reaction mixture is treated with fluoride to remove the 2′-O-tent-butyldimethylsilyl protecting groups. The crude product is then purified to obtain the chemically modified RNA.
  • Figure US20160348109A1-20161201-C00002
    Figure US20160348109A1-20161201-C00003
  • Click Reaction between Benzyl Azide and RNA
  • Lyophilized crude RNA (˜50 nmol) containing at least one alkyne functional group (shown below) in 96-well format was dissolved in DMSO:water (75:25, 40 μL). Benzyl azide (1M in DMSO, 40 μL) was added, followed by a freshly prepared solution of CuBr·Me2S in DMSO (12 mM, 40 μL). The reaction block was sealed and heated at 65-80° C. overnight. The solution was cooled to room temperature and ammonium fluoride (100 μL, 5.4M in water) was added. The solution was heated at 65° C. for 1 h, cooled to room temperature and diluted with 1M aqueous NaCl (800 μL). The crude product was purified on a C18 cartridge to afford the desired chemically modified benzyl-triazole-linked RNA as determined by HPLC and LC-MS analyses.
  • Figure US20160348109A1-20161201-C00004
  • Click Reaction between Azidomethyl Phenyl Sulfide and RNA
  • Crude RNA (˜50 nmol) containing at least one alkyne functional group (shown below) was dissolved in DMSO:water (75:25, 40 μL). Azidomethyl phenyl sulfide (1M in DMSO, 40 μL) was added, followed by a freshly prepared solution of CuBr·Me2S in DMSO (12 mM, 40 μL). The reaction block was sealed and heated to 65-80° C. overnight. The solution was cooled to room temperature and ammonium fluoride (100 μL, 5.4M in water) was added. The solution was heated at 65° C. for 1 h, cooled to room temperature and diluted with 1M aqueous NaCl (800 μL). The crude product was purified on a C18 cartridge to afford the desired chemically modified phenylthiomethyl-triazole-linked RNA as determined by HPLC and LC-MS analyses.
  • Figure US20160348109A1-20161201-C00005
  • Click Reaction between Ethyl Azidoacetate and RNA
  • Crude RNA (˜50 nmol) containing at least one alkyne functional group (shown below) was dissolved in DMSO:water (75:25, 40 μL). Ethyl azidoacetate (1M in DMSO, 40 μL) was added, followed by a freshly prepared solution of CuBr·Me2S in DMSO (12 mM, 40 μL). The reaction block was sealed and heated to 65-80° C. overnight. The solution was cooled to room temperature and ammonium fluoride (100 μL, 5.4M in water) was added. The solution was heated at 65° C. for 1 h, cooled to room temperature and diluted with 1M aqueous NaCl (800 μL). The crude product was purified on a C18 cartridge to afford the desired chemically modified ethyl-carboxymethyl-1,4-triazole-linked RNA as determined by HPLC and LC-MS analyses.
  • Figure US20160348109A1-20161201-C00006
  • Click Reaction between N-Acetylgalactosamine Azide and RNA
  • Crude RNA (˜50 nmol) containing at least one alkyne functional group (shown below) was dissolved in DMSO:water (75:25, 40 μL). Modified N-acetyl galactosamine azide (1M in DMSO, 40 μL) was added, followed by a freshly prepared solution of CuBr·Me2S in DMSO (12 mM, 40 μL). The reaction block was sealed and heated to 65-80° C. overnight. The solution was cooled to room temperature and ammonium fluoride (100 μL, 5.4M in water) was added. The solution was heated at 65° C. for 1 h, cooled to room temperature and diluted with 1M aqueous NaCl (800 μL). The crude product was purified on a C18 cartridge to afford the desired chemically modified N-acetylgalactosamine-1,4-triazole-linked RNA as determined by HPLC and LC-MS analyses.
  • Figure US20160348109A1-20161201-C00007
  • Click Reaction between N-Acetylgalactosamine Azide and RNA (Multi-Click)
  • Crude RNA (˜50 nmol) containing more than one alkyne functional group (shown below) was dissolved in DMSO:water (75:25, 40 μL). Modified N-acetylgalactosamine azide (1M in DMSO, 40 μL) was added, followed by a freshly prepared solution of CuBr·Me2S in DMSO (12 mM, 40 μL). The reaction block was sealed and heated to 65-80° C. overnight. The solution was cooled to room temperature and ammonium fluoride (100 μL, 5.4M in water) was added. The solution was heated at 65° C. for 1 h, cooled to room temperature and diluted with 1M aqueous NaCl (800 μL). The crude product was purified on a C18 cartridge to afford the desired chemically modified N-acetylgalactosamine-1,4-triazole-linked RNA as determined by HPLC and LC-MS analyses.
  • Figure US20160348109A1-20161201-C00008
  • Click Reaction Walkthrough between Benzyl Azide and SSB(291) RNA
  • Crude RNA (50 nmol) containing at least one alkyne functional group (shown below) was dissolved in DMSO:water (75:25, 40 uL). Benzyl azide (1M in DMSO, 40 uL) was added, followed by a freshly prepared solution of CuBr·Me2S in DMSO (12 mM, 40 uL). The reaction block was sealed and heated at 65-80° C. overnight. The solution was cooled to room temperature and ammonium fluoride (100 μL, 5.4M in water) was added. The solution was heated at 65° C. for 1 h, cooled to room temperature and diluted with 1M aqueous NaCl (800 uL). The crude product was purified on a C18 cartridge to afford the desired chemically modified benzyl-1,4-triazole-linked RNA as determined by HPLC and LC-MS analyses.
  • Figure US20160348109A1-20161201-C00009
  • Click Reaction between 11-Azido-3,6,9-Trioxaundecan-1-Amine and SSB(291) RNA
  • Crude RNA (50 nmol) containing at least one alkyne functional group (shown below) was dissolved in DMSO:water (75:25, 40 uL). 11-Azido-3,6,9-trioxaundecan-1-amine (1M in DMSO, 40 uL) was added, followed by a freshly prepared solution of CuBr·Me2S in DMSO (12 mM, 40 uL). The reaction block was sealed and heated at 65-80° C. overnight. The solution was cooled to room temperature and ammonium fluoride (100 μL, 5.4M in water) was added. The solution was heated at 65° C. for 1 h, cooled to room temperature and diluted with 1M aqueous NaCl (800 uL). The crude product was purified on a C18 cartridge to afford the desired chemically modified amino-PEG-1,4-triazole-linked RNA as determined by HPLC and LC-MS analyses.
  • Figure US20160348109A1-20161201-C00010
    • Click Reaction on Unprotected “Free” RNA
  • Purified deprotected free RNA (8.6 mg, sequence=UUA CAU UAA (2′-propargylabasic)GU CUG UUG UdTdT) (SEQ ID NO: 1) was dissolved in DMSO:water (75:25, 1 mL). The solution (75 μL) was dispensed in wells containing stir bars. A bright blue-green solution (75 μL) of tris(1-(O-ethylcarboxymethyl)-1H-1,2,3-triazol-4-ylmethypamineligand (50 mg) and CuBr (10 mg, 99.999%) in DMSO:water (75:25, 5 mL) was added. Phenylthiomethyl azide (5 μL) was added. The reaction block was sealed and agitated overnight at room temperature. The crude product was purified to afford the desired chemically modified phenylthiomethyl-1,4-triazole-linked RNA as determined by HPLC and LC-MS analyses.
  • Figure US20160348109A1-20161201-C00011
    • Click Reaction on Unprotected “Free” RNA
  • Purified deprotected free RNA (8.6 mg, sequence=UUA CAU UAA (2′-propargylabasic)GU CUG UUG UdTdT) (SEQ ID NO: 1) was dissolved in DMSO:water (75:25, 1 mL). The solution (75 μL) was dispensed in wells containing stir bars. A bright blue-green solution (75 μL) of tris(1-(O-ethylcarboxymethyl)-1H-1,2,3-triazol-4-ylmethyl)amine ligand (50 mg) and CuBr (10 mg, 99.999%) in DMSO:water (75:25, 5 mL) was added. Benzyl azide (5 μL) was added. The reaction block was sealed and agitated overnight at room temperature. The crude product was purified to afford the desired chemically modified benzyl-1,4-triazole-linked RNA as determined by HPLC and LC-MS analyses.
  • Figure US20160348109A1-20161201-C00012
    • Click Reaction on Unprotected “Free” RNA
  • Purified deprotected free RNA (8.6 mg, sequence=UUA CAU UAA (2′-propargylabasic)GU CUG UUG UdTdT) (SEQ ID NO: 1) was dissolved in DMSO:water (75:25, 1 mL). The solution (75 !IL) was dispensed in wells containing stir bars. A bright blue-green solution (75 μL) of tris(1-(O-ethylcarboxymethyl)-1H-1,2,3-triazol -4-ylmethyl)amine ligand (50 mg) and CuBr (10 mg, 99.999%) in DMSO:water (75:25, 5 mL) was added. Ethyl azidoacetate (15 μL, 25-30%wt in EtOH) was added. The reaction block was sealed and agitated overnight at room temperature. The crude product was purified to afford the desired chemically modified ethyl carboxymethyl-L4-triazole-linked RNA as determined by HPLC and LC-MS analyses.
  • Figure US20160348109A1-20161201-C00013
    • Assays
  • Position
    in mRNA Guide strand
    Gene sequence sequence (5′-3′) SEQ ID NO
    SSB 291 UUACAUUAAAGUCUGUUGU 2
    Luc 80 UAUCUCUUCAUAGCCUUAU 3
  • Positions 1-19 of both strands were ribonucleotides, and the overhangs at positions 20 and 21 contained 2′-deoxyribonucleotide thymidines. This unmodified siRNA was the template for systematic evaluation of modified siRNAs containing a single modification at every position along the guide strand. In order to examine the effect of the chemical modifications for the SSB sequence, we synthesized the RNA oligomers with the first nucleotide, uridine (U), replaced with 2′-O-propargyl-inosine. Then, a second sequence, in which the second nucleoside (U) was replaced with 2′-O-propargyl-inosine was synthesized, keeping all other nucleotides unchanged. Altogether nineteen sequences were synthesized where the universal base replaced all the natural nucleosides in that sequence. This “modification walkthrough” is depicted in Table 1 for SSB(291). The desired chemical modification was then introduced into the assembled RNA by the methods described in Schemes 6 and 7.
  • TABLE 1
    Position
    in mRNA Guide strand SEQ
    Entry Gene sequence sequence (5′-3′) ID NO
    unmodified SSB 291 UUACAUUAAAGUCUGUUGU 2
    1 SSB 291 NUACAUUAAAGUCUGUUGU 4
    2 SSB 291 UNANAUUAAAGUCUGUUGU 5
    3 SSB 291 UUNCNUUAAAGUCUGUUGU 6
    4 SSB 291 UUANAUUAAAGUCUGUUGU 7
    5 SSB 291 UUACNUUAAAGUCUGUUGU 8
    6 SSB 291 UUACANUAAAGUCUGUUGU 9
    7 SSB 291 UUACAUNAAAGUCUGUUGU 10
    8 SSB 291 UUACAUUNAAGUCUGUUGU 11
    9 SSB 291 UUACAUUANAGUCUGUUGU 12
    10 SSB 291 UUACAUUAANGUCUGUUGU 13
    11 SSB 291 UUACAUUAAANUCUGUUGU 14
    12 SSB 291 UUACAUUAAAGNCUGUUGU 15
    13 SSB 291 UUACAUUAAAGUNUGUUGU 16
    14 SSB 291 UUACAUUAAAGUCNGUUGU 17
    15 SSB 291 UUACAUUAAAGUCUNUUGU 18
    16 SSB 291 UUACAUUAAAGUCUGNUGU 19
    17 SSB 291 UUACAUUAAAGUCUGUNGU 20
    18 SSB 291 UUACAUUAAAGUCUGUUNU 21
    19 SSB 291 UUACAUUAAAGUCUGUUGN 22
    (N represents a universal base such as inosine)
    • SSB Knockdown
  • In a 96-well format, Hepal-6 cells were transfected with 10 nM of either the unmodified, modified, or negative control siRNA using a commercial lipid transfection reagent. The target mRNA was assessed for degradation using standard Taqman procedures.
    • Modified Multiplex Luciferase Report Assay for in Vitro Duration Study Assay Principle
  • Multiplex luciferase assay for in vitro duration study is modified from the manufacturer's instruction using HeLa-luc cell line. Briefly, the cell viability and the luciferease expression at the same well are determined by CellTiter-Fluor™ (Promega, Cat# G6082) and Bright-Glo™ (Promega Cat# E2620) sequentially.
  • HeLa-luc cell line is a stable firefly luciferase reporter expression cell line. Bright-Glo™ luciferase assay system contains the stable substrate—luciferin and assay buffer. The luminescent reaction of luciferease and luciferin has high quantum yield and can be detected as luminescence intensity, which represents the luciferase expression level.
  • Target siRNAs containing luciferase coding region is designed to be transfected into the HeLa-luc cells. Once the taget is effected, the luciferase expression is reduced accordingly, Therefore, the siRNA silencing efficacy can be determined by the relative luminecence intensity of treated cells.
  • To reduce the variation caused by cell viability and cell plating process, the cell viability of the same treatment wells is measured using CellTiter-fluor kit. This assay measures the conserved and constitutive protease activity within live cells and therefore serves as a marker of cell viability, using a fluorogenic, cell-permeable peptide substrate (glycyl-phenylalanyl-aminofluorocoumarin; GF-AFC).
    • Experiment Design
  • Luciferase stable expressed HeLa-luc cell cells are plated in 96-well plates at density of 4,500 cells per well in 100 μL DMEM media without antibiotics 24 hours prior to transfection. siRNA transfection is performed using the RNAiMAX™ (Invitrogen). Briefly, 0.05 μM siRNA are mixed with Opti-MEMmedia and RNAiMAX and incubated at room temperature for 15 min. The mix is then added to the cells. The final siRNA concentration is 1 nM. Cell plates for all time points are transfected at same time with a medium change at 6 hours post-transfection into 100 μL of fresh completed DMEM (DMEM+10% FBS+Pen/strep).
  • In vitro duration is determined by the luciferase expression post-transfection at four time points: day 1, day 2, day 5 and day 7. Addition medium changes are performed at day 2 and day 5 into 100 μL of fresh completed DMEM (DMEM+10% FBS+Penn/strep). Luciferase levels are determined using the Bright-Glo Luminescence Assay (Promega) and measuring the wells on an Envison instrument (Perkin Elmer) according to manufacturer's instructions.
  • To reduce the variation caused by cell viability and cell plating process, the cell viability of the same treatment wells is measured using CellTiter-fluor kit (Promega) according to manufacturer's instructions. This assay measures the conserved and constitutive protease activity within live cells and therefore servers as a marker of cell viability, using a fluorogenic, cell-permeable peptide substrate (glycyl-phenylalanyl-aminofluorocoumarin; GF-AFC). The fluorescence was measured on the Envision using exciton filter at 405 nm and emission filter at 510 nm.
  • The luciferase expression was normalized to cell viability. The log of this number was calculated to determine the luciferase protein that was degraded (knockdown). A non-targeting siRNA was subtracted from this value to account for non-specific background.
    • EXAMPLES
  • The following Examples 1-6 were generated utilizing the Assays above and demonstrate the utility of the RNAs made by the methods described in the Schemes. As demonstrated, the RNAs made by the process of the invention are useful in high-throughput structure-activity relationship studies on chemically modified RNA in 96-well format.
    • Example 1
  • In FIG. 1, the impact on knockdown of the 2′-O-benzyl-triazole inosine chemical modification was systematically evaluated along positions 1 through 19 of the guide strand of an siRNA targeting mRNA SSB(291).
    • Example 2
  • In FIG. 2, the impact of the 2′-O-phenylthiomethyl-triazole inosine chemical modification was systematically evaluated along positions 1 through 19 of the guide strand of an siRNA targeting mRNA SSB(291).
    • Example 3
  • In FIG. 3, the impact on knockdown of the 2′-O-benzyl-triazole inosine chemical modification was systematically evaluated along positions 1 through 19 of the guide strand of an siRNA targeting mRNA Luc(80).
    • Example 4
  • In FIG. 4, the impact of the 2′-O-phenylthiomethyl-triazole inosine chemical modifications were systematically evaluated along positions 1 through 19 of the guide strand of an siRNA targeting mRNA Luc(80).
    • Example 5
  • In FIG. 5, the impact on duration of knockdown activity of the 2′-O-benzyl-triazole inosine chemical modification was systematically evaluated along positions 1 through 19 of the guide strand of an siRNA targeting mRNA Luc(80).
    • Example 6
  • In FIG. 6, the impact on duration of knockdown activity of the 2′-O-phenylthiomethyl inosine chemical modification was systematically evaluated along positions 1 through 19 of the guide strand of an siRNA targeting mRNA Luc(80).
    • Example 7
  • In FIG. 7, the liver targeting compound N-acetyl-galactosamine (NAG) can be introduced as a chemical modification that may help with specific cell targeting, cellular uptake and delivery of RNA.
    • Example 8
  • In FIG. 8, poly(ethylene)glycol amines can be introduced to improve solubility properties, cellular uptake, immune stealth, reduce metabolic clearance and delivery of RNA.
    • Example 9
  • In FIG. 9, the “click” reaction can be utilized to introduce multiple chemical modifications in one synthetic operation. For example, the click reaction was performed to introduce three units of protected N-acetylgalactosamine on RNA. This may lead to improved physical properties towards solubility, cellular uptake, and delivery of siRNA.

Claims (1)

What is claimed is:
1. A process for introducing 2′-modifications into RNA, said process comprises a) obtaining RNA with an alkyne functional group at the 2′-position on at least one ribose ring; b) creating a solution of RNA in a solvent; and c) adding an organic azide and a metal catalyst to the solution to form a reaction and creating a 2′-modified RNA.
US15/234,736 2010-01-22 2016-08-11 Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry Abandoned US20160348109A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/234,736 US20160348109A1 (en) 2010-01-22 2016-08-11 Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US29737710P 2010-01-22 2010-01-22
US32590810P 2010-04-20 2010-04-20
PCT/US2011/021629 WO2011090968A1 (en) 2010-01-22 2011-01-19 Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
US201213574136A 2012-07-19 2012-07-19
US14/609,118 US9441228B2 (en) 2010-01-22 2015-01-29 Post-synthetic chemical modification of RNA at the 2′-position of the ribose ring via “click” chemistry
US15/234,736 US20160348109A1 (en) 2010-01-22 2016-08-11 Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/609,118 Continuation US9441228B2 (en) 2010-01-22 2015-01-29 Post-synthetic chemical modification of RNA at the 2′-position of the ribose ring via “click” chemistry

Publications (1)

Publication Number Publication Date
US20160348109A1 true US20160348109A1 (en) 2016-12-01

Family

ID=44307168

Family Applications (4)

Application Number Title Priority Date Filing Date
US13/574,315 Active 2031-04-14 US9670487B2 (en) 2010-01-22 2011-01-19 Cationic lipids for oligonucleotide delivery
US13/574,136 Abandoned US20130116419A1 (en) 2010-01-22 2011-01-19 Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
US14/609,118 Active US9441228B2 (en) 2010-01-22 2015-01-29 Post-synthetic chemical modification of RNA at the 2′-position of the ribose ring via “click” chemistry
US15/234,736 Abandoned US20160348109A1 (en) 2010-01-22 2016-08-11 Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US13/574,315 Active 2031-04-14 US9670487B2 (en) 2010-01-22 2011-01-19 Cationic lipids for oligonucleotide delivery
US13/574,136 Abandoned US20130116419A1 (en) 2010-01-22 2011-01-19 Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
US14/609,118 Active US9441228B2 (en) 2010-01-22 2015-01-29 Post-synthetic chemical modification of RNA at the 2′-position of the ribose ring via “click” chemistry

Country Status (3)

Country Link
US (4) US9670487B2 (en)
EP (2) EP2525781A1 (en)
WO (1) WO2011090965A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150322433A1 (en) * 2012-12-20 2015-11-12 Sirna Therapeutics, Inc. POST-SYNTHETIC ORTHOGANAL AMIDATION PLUS METAL CATALYZED AZIDE-ALKYNE CYCLOADDITION CLICK CHEMISTRY ON siRNA

Families Citing this family (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2525781A1 (en) * 2010-01-22 2012-11-28 Schering Corporation Novel cationic lipids for oligonucleotide delivery
PT3597644T (en) 2011-10-18 2021-11-03 Dicerna Pharmaceuticals Inc Amine cationic lipids and uses thereof
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
AU2012356239B2 (en) * 2011-11-04 2016-09-22 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
CA2856742A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
AU2013243949A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
HRP20220607T1 (en) 2012-11-26 2022-06-24 Modernatx, Inc. Terminally modified rna
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US11027025B2 (en) 2013-07-11 2021-06-08 Modernatx, Inc. Compositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EA201690675A1 (en) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. POLYNUCLEOTES ENCODING THE RECEPTOR OF LOW DENSITY LIPOPROTEINS
SI3071696T1 (en) 2013-11-22 2019-11-29 Mina Therapeutics Ltd C / EBP alpha short-acting RNA compositions and application processes
ES2821758T3 (en) 2014-01-21 2021-04-27 Anjarium Biosciences Ag Process for the production of hybridomes
HRP20221536T1 (en) 2014-06-25 2023-02-17 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3169693B1 (en) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimeric polynucleotides
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
WO2016065349A2 (en) 2014-10-24 2016-04-28 University Of Maryland, Baltimore Short non-coding protein regulatory rnas (sprrnas) and methods of use
EP3313829B1 (en) 2015-06-29 2024-04-10 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE CYTOMEGALOVIRUS HUMAN
IL307179A (en) 2015-10-28 2023-11-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
SI3394093T1 (en) 2015-12-23 2022-05-31 Modernatx, Inc. Methods of using ox40 ligand encoding polynucleotides
CA3009131C (en) * 2015-12-25 2024-06-04 Kyowa Hakko Kirin Co., Ltd. Compounds as cationic lipids and their use in nucleic acid delivery compositions
MA43587A (en) 2016-01-10 2018-11-14 Modernatx Inc THERAPEUTIC RNA CODING FOR ANTI-CTLA-4 ANTIBODIES
EP3625246A1 (en) 2017-05-18 2020-03-25 ModernaTX, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
MA49395A (en) 2017-06-14 2020-04-22 Modernatx Inc POLYNUCLEOTIDES COAGULATION FACTOR VIII CODING
WO2019048645A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
EP3679138B1 (en) 2017-09-08 2023-03-22 MiNA Therapeutics Limited Hnf4a sarna compositions and methods of use
US20190231690A1 (en) 2017-11-08 2019-08-01 L.E.A.F. Holdings Group Llc Platinum complexes and uses thereof
JP7491572B2 (en) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー Alpha polyglutamated pemetrexed and uses thereof
CA3090483A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated pemetrexed and uses thereof
WO2019197845A1 (en) 2018-04-12 2019-10-17 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
KR20250159271A (en) 2018-05-03 2025-11-10 엘.이.에이.에프. 홀딩스 그룹 엘엘씨. Carotenoid compositions and uses thereof
US11904081B2 (en) 2018-05-11 2024-02-20 Lupagen, Inc. Systems and methods for closed loop, real-time modifications of patient cells
WO2020033791A1 (en) 2018-08-09 2020-02-13 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
CN112996854B (en) 2018-09-19 2024-08-30 摩登纳特斯有限公司 High-purity PEG lipids and their uses
WO2020061284A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
WO2020061426A2 (en) 2018-09-21 2020-03-26 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
BR112021009422A2 (en) 2018-12-21 2021-10-26 Curevac Ag RNA FOR VACCINES AGAINST MALARIA
IL284535B2 (en) 2019-01-11 2025-03-01 Acuitas Therapeutics Inc Lipids for lipid nanoparticle delivery of active agents
EP4491229A3 (en) 2019-02-08 2025-05-14 CureVac SE Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
EP3953473A1 (en) 2019-04-12 2022-02-16 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
US20220313813A1 (en) 2019-06-18 2022-10-06 Curevac Ag Rotavirus mrna vaccine
CN114423869A (en) 2019-07-19 2022-04-29 旗舰先锋创新Vi有限责任公司 Recombinase compositions and methods of use
CN114555127A (en) 2019-08-06 2022-05-27 L.E.A.F.控股集团公司 Method for preparing polyglutamated antifolates and use of compositions thereof
CA3144902A1 (en) 2019-08-14 2022-01-19 Andreas Thess Rna combinations and compositions with decreased immunostimulatory properties
EP4041894A1 (en) 2019-09-23 2022-08-17 Omega Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4a) GENE EXPRESSION
WO2021061707A1 (en) 2019-09-23 2021-04-01 Omega Therapeutics, Inc. Compositions and methods for modulating apolipoprotein b (apob) gene expression
CA3160511A1 (en) 2020-02-04 2021-08-12 Susanne RAUCH Coronavirus vaccine
WO2021183720A1 (en) 2020-03-11 2021-09-16 Omega Therapeutics, Inc. Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
CN115667530A (en) 2020-03-24 2023-01-31 世代生物公司 Non-viral DNA vectors and their use for expressing factor IX therapeutics
KR20230003478A (en) 2020-03-24 2023-01-06 제너레이션 바이오 컴퍼니 Non-viral DNA vectors and their use for expressing Gaucher therapeutics
JP2023526423A (en) 2020-05-20 2023-06-21 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー Immunogenic compositions and uses thereof
CA3179420A1 (en) 2020-05-20 2021-11-25 Avak Kahvejian Coronavirus antigen compositions and their uses
AU2021278984A1 (en) 2020-05-29 2022-11-17 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods relating thereto
CN116322758A (en) 2020-05-29 2023-06-23 库尔维科欧洲股份公司 Nucleic acid-based combination vaccines
AU2021281453A1 (en) 2020-05-29 2022-11-17 Flagship Pioneering Innovations Vi, Llc. Trem compositions and methods relating thereto
CN116096702A (en) 2020-07-16 2023-05-09 爱康泰生治疗公司 Cationic Lipids for Lipid Nanoparticles
AU2021314809A1 (en) 2020-07-27 2023-02-23 Anjarium Biosciences Ag Compositions of DNA molecules, methods of making therefor, and methods of use thereof
CA3170741A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
MA71659A (en) 2020-08-06 2025-05-30 Modernatx, Inc. COMPOSITIONS FOR DELIVERING PAYLOAD MOLECULES TO THE RESPIRATORY TRACT EPITHELIUM
US20240066114A1 (en) 2020-08-31 2024-02-29 CureVac SE Multivalent nucleic acid based coronavirus vaccines
MX2023002439A (en) 2020-09-03 2023-05-09 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof.
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
CA3171051A1 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
MX2023007630A (en) 2020-12-23 2023-08-25 Flagship Pioneering Innovations Vi Llc Compositions of modified trems and uses thereof.
WO2022162027A2 (en) 2021-01-27 2022-08-04 Curevac Ag Method of reducing the immunostimulatory properties of in vitro transcribed rna
JP2024511092A (en) 2021-03-26 2024-03-12 ミナ セラピューティクス リミテッド TMEM173saRNA composition and method of use
CA3212653A1 (en) 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Immunogenic compositions
US20250345524A1 (en) 2021-03-31 2025-11-13 CureVac SE Syringes containing pharmaceutical compositions comprising rna
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
EP4326860A1 (en) 2021-04-20 2024-02-28 Anjarium Biosciences AG Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
JP2024515788A (en) 2021-04-27 2024-04-10 ジェネレーション バイオ カンパニー Non-viral DNA vectors expressing therapeutic antibodies and uses thereof
US20240216535A1 (en) 2021-04-27 2024-07-04 Generation Bio Co. Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
CA3171589A1 (en) 2021-05-03 2022-11-03 Moritz THRAN Improved nucleic acid sequence for cell type specific expression
US20240271162A1 (en) 2021-06-11 2024-08-15 LifeEDIT Therapeutics, Inc. Rna polymerase iii promoters and methods of use
WO2023283359A2 (en) 2021-07-07 2023-01-12 Omega Therapeutics, Inc. Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
US20240336945A1 (en) 2021-07-26 2024-10-10 Flagship Pioneering Innovations Vi, Llc Trem compositions and uses thereof
US20240350621A1 (en) 2021-08-06 2024-10-24 University Of Iowa Research Foundation Double stranded mrna vaccines
WO2023023055A1 (en) 2021-08-16 2023-02-23 Renagade Therapeutics Management Inc. Compositions and methods for optimizing tropism of delivery systems for rna
WO2023031394A1 (en) 2021-09-03 2023-03-09 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
CN117940158A (en) 2021-09-03 2024-04-26 库瑞瓦格欧洲公司 Novel lipid nanoparticles comprising phosphatidylserine for nucleic acid delivery
WO2023031855A1 (en) 2021-09-03 2023-03-09 Glaxosmithkline Biologicals Sa Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
CA3231523A1 (en) 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Acyclic lipids and methods of use thereof
JP2024533865A (en) 2021-09-14 2024-09-12 レナゲード セラピューティクス マネージメント インコーポレイテッド Cyclic lipids and methods of use thereof
WO2023044006A1 (en) 2021-09-17 2023-03-23 Flagship Pioneering Innovations Vi, Llc Compositions and methods for producing circular polyribonucleotides
CA3235625A1 (en) 2021-10-18 2023-04-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
US20250027108A1 (en) 2021-10-29 2025-01-23 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023081756A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
MX2024005521A (en) 2021-11-08 2024-05-21 Orna Therapeutics Inc Lipid nanoparticle compositions for delivering circular polynucleotides.
CN118829423A (en) 2021-11-12 2024-10-22 摩登纳特斯有限公司 Compositions for delivering payload molecules to airway epithelium
CA3238735A1 (en) 2021-11-24 2023-06-01 Jennifer A. Nelson Immunogenic compositions and their uses
MX2024006261A (en) 2021-11-24 2024-08-14 Flagship Pioneering Innovations Vi Llc Coronavirus immunogen compositions and their uses.
AU2022397292A1 (en) 2021-11-24 2024-05-30 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
JP2024546952A (en) 2021-12-16 2024-12-26 アクイタス セラピューティクス インコーポレイテッド Lipids for use in lipid nanoparticle formulations
EP4448758A1 (en) 2021-12-17 2024-10-23 Flagship Pioneering Innovations VI, LLC Methods for enrichment of circular rna under denaturing conditions
CN118679254A (en) 2021-12-22 2024-09-20 旗舰创业创新六公司 Compositions and methods for purifying polyribonucleotides
TW202342064A (en) 2021-12-23 2023-11-01 美商旗艦先鋒創新有限責任公司 Circular polyribonucleotides encoding antifusogenic polypeptides
WO2023122752A1 (en) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
WO2023135273A2 (en) 2022-01-14 2023-07-20 Anjarium Biosciences Ag Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
US20250235531A1 (en) 2022-02-09 2025-07-24 Modernatx, Inc. Mucosal administration methods and formulations
EP4482962A1 (en) 2022-02-24 2025-01-01 IO Biotech ApS Nucleotide delivery of cancer therapy
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
AU2023235112A1 (en) 2022-03-14 2024-10-17 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
JP2025510229A (en) 2022-03-25 2025-04-14 セイル バイオメディシンズ インコーポレイテッド Novel ionized lipids and lipid nanoparticles and methods of using them
WO2023196931A1 (en) 2022-04-07 2023-10-12 Renagade Therapeutics Management Inc. Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
JP2025511756A (en) 2022-04-08 2025-04-16 フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー Vaccines and Related Methods
AU2023269030A1 (en) 2022-05-09 2024-11-14 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
EP4522753A2 (en) 2022-05-13 2025-03-19 Flagship Pioneering Innovations VII, LLC Double stranded dna compositions and related methods
CN119212720A (en) 2022-05-25 2024-12-27 库瑞瓦格欧洲股份公司 Nucleic acid-based vaccines encoding Escherichia coli FimH antigenic polypeptides
WO2023239756A1 (en) 2022-06-07 2023-12-14 Generation Bio Co. Lipid nanoparticle compositions and uses thereof
EP4539876A2 (en) 2022-06-18 2025-04-23 GlaxoSmithKline Biologicals S.A. Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
US20250179492A1 (en) 2022-06-22 2025-06-05 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
CN120344660A (en) 2022-07-18 2025-07-18 雷纳嘉德医疗管理公司 Gene editing components, systems and methods of use
EP4565604A2 (en) 2022-08-01 2025-06-11 Flagship Pioneering Innovations VII, LLC Immunomodulatory proteins and related methods
CN120112633A (en) 2022-08-12 2025-06-06 生命编辑治疗股份有限公司 RNA-guided nucleases and active fragments and variants thereof and methods of use
WO2024035952A1 (en) 2022-08-12 2024-02-15 Remix Therapeutics Inc. Methods and compositions for modulating splicing at alternative splice sites
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
CA3265596A1 (en) 2022-08-31 2024-03-07 Sail Biomedicines Inc Novel ionizable lipids and lipid nanoparticles and methods of using the same
EP4342460A1 (en) 2022-09-21 2024-03-27 NovoArc GmbH Lipid nanoparticle with nucleic acid cargo
AU2023353931A1 (en) 2022-09-26 2025-03-20 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
DE202023106198U1 (en) 2022-10-28 2024-03-21 CureVac SE Nucleic acid-based vaccine
WO2024097664A1 (en) 2022-10-31 2024-05-10 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
TW202425959A (en) 2022-11-08 2024-07-01 美商歐納醫療公司 Lipids and nanoparticle compositions for delivering polynucleotides
WO2024102799A1 (en) 2022-11-08 2024-05-16 Flagship Pioneering Innovations Vi, Llc Compositions and methods for producing circular polyribonucleotides
TW202428289A (en) 2022-11-08 2024-07-16 美商歐納醫療公司 Circular rna compositions
EP4626444A2 (en) 2022-12-01 2025-10-08 Generation Bio Co. Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses
WO2024119103A1 (en) 2022-12-01 2024-06-06 Generation Bio Co. Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
AU2023406483A1 (en) 2022-12-01 2025-05-29 Generation Bio Co. Stealth lipid nanoparticle compositions for cell targeting
WO2024119051A1 (en) 2022-12-01 2024-06-06 Generation Bio Co. Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
EP4630057A1 (en) 2022-12-08 2025-10-15 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
TW202430215A (en) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 Compositions and methods for delivery of therapeutic agents to bone
EP4634388A1 (en) 2022-12-14 2025-10-22 Providence Therapeutics Holdings Inc. Compositions and methods for infectious diseases
CN120456919A (en) 2022-12-19 2025-08-08 葛兰素史克生物有限公司 Hepatitis B composition
WO2024134199A1 (en) 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use
WO2024151685A1 (en) 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant nucleic acid molecules and their use in wound healing
TW202438673A (en) 2023-01-09 2024-10-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 Vaccines and related methods
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
US20240238473A1 (en) 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant nucleic acid molecules and their use in wound healing
WO2024160936A1 (en) 2023-02-03 2024-08-08 Glaxosmithkline Biologicals Sa Rna formulation
US20240269263A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
IL322468A (en) 2023-02-13 2025-09-01 Flagship Pioneering Innovations Vii Llc Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
US20240285805A1 (en) 2023-02-17 2024-08-29 Flagship Pioneering Innovations Vii, Llc Dna compositions comprising modified uracil
WO2024173836A2 (en) 2023-02-17 2024-08-22 Flagship Pioneering Innovations Vii, Llc Dna compositions comprising modified cytosine
KR20250153298A (en) 2023-03-08 2025-10-24 큐어백 에스이 Novel lipid nanoparticle formulations for nucleic acid delivery
WO2024192422A1 (en) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
AU2024235803A1 (en) 2023-03-15 2025-09-25 Flagship Pioneering Innovations Vi, Llc Compositions comprising polyribonucleotides and uses thereof
WO2024192277A2 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024192291A1 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
WO2024216191A1 (en) 2023-04-12 2024-10-17 Flagship Pioneering Innovations Vi, Llc Modified trems, compositions, and related methods thereof
AU2024252590A1 (en) 2023-04-12 2025-10-23 Flagship Pioneering Innovations Vi, Llc Trems for use in correction of missense mutations
WO2024220746A2 (en) 2023-04-21 2024-10-24 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting fatty acid synthase and related methods
WO2024223724A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
AU2024260120A1 (en) 2023-04-27 2025-11-06 Glaxosmithkline Biologicals Sa Influenza virus vaccines
AU2024269222A1 (en) 2023-05-05 2025-10-09 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2024243438A2 (en) 2023-05-23 2024-11-28 Omega Therapeutics, Inc. Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
WO2024258829A1 (en) 2023-06-12 2024-12-19 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025006684A1 (en) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
WO2025007148A1 (en) 2023-06-30 2025-01-02 Orna Therapeutics, Inc. Polymer lipid nanoparticle compositions for delivering circular polynucleotides
WO2025011529A2 (en) 2023-07-07 2025-01-16 Shanghai Circode Biomed Co., Ltd. Circular rna vaccines for seasonal flu and methods of uses
TW202516001A (en) 2023-07-25 2025-04-16 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 Cas endonucleases and related methods
WO2025022367A2 (en) 2023-07-27 2025-01-30 Life Edit Therapeutics, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
WO2025045142A1 (en) 2023-08-29 2025-03-06 Shanghai Circode Biomed Co., Ltd. Circular rna encoding vegf polypeptides, formulations, and methods of uses
WO2025046121A1 (en) 2023-09-01 2025-03-06 Novoarc Gmbh Lipid nanoparticle with nucleic acid cargo and ionizable lipid
WO2025049959A2 (en) 2023-09-01 2025-03-06 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025054236A2 (en) 2023-09-06 2025-03-13 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
EP4520345A1 (en) 2023-09-06 2025-03-12 Myneo Nv Product
WO2025052180A2 (en) 2023-09-07 2025-03-13 Axelyf ehf. Lipids and lipid nanoparticles
US20250268826A1 (en) 2023-09-18 2025-08-28 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
WO2025072331A1 (en) 2023-09-26 2025-04-03 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025083619A1 (en) 2023-10-18 2025-04-24 Life Edit Therapeutics, Inc. Rna-guided nucleases and acive fragments and variants thereof and methods of use
WO2025096807A2 (en) 2023-10-31 2025-05-08 Flagship Pioneering Innovations Vii, Llc Novel therapeutic dna forms
WO2025101501A1 (en) 2023-11-07 2025-05-15 Orna Therapeutics, Inc. Circular rna compositions
WO2025106670A1 (en) 2023-11-14 2025-05-22 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
WO2025111526A1 (en) 2023-11-22 2025-05-30 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease
US12364773B2 (en) 2023-12-01 2025-07-22 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
WO2025117877A2 (en) 2023-12-01 2025-06-05 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025126113A1 (en) * 2023-12-15 2025-06-19 Pfizer Inc. Lipid compounds and uses thereof
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2025137646A1 (en) 2023-12-22 2025-06-26 Recode Therapeutics, Inc. Gene editing methods and compositions for treating cystic fibrosis
WO2025144938A1 (en) 2023-12-26 2025-07-03 Emmune, Inc. Systems for nucleic acid transfer
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025160334A1 (en) 2024-01-26 2025-07-31 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025166238A1 (en) 2024-01-31 2025-08-07 Orna Therapeutics, Inc. Fast-shedding polyethylene glycol lipids
WO2025174908A1 (en) 2024-02-12 2025-08-21 Life Edit Therapeutics, Inc. Novel rna-guided nucleases and proteins for polymerase editing
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025194019A1 (en) 2024-03-14 2025-09-18 Flagship Pioneering Innovations Vii, Llc Methods for treating liver fibrosis and non-alcoholic fatty liver disease
WO2025194138A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. St1cas9 compositions and methods for modulating a genome
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation
WO2025217129A1 (en) * 2024-04-08 2025-10-16 Popvax Private Limited Novel lipids for delivery of nucleic acid therapeutics
WO2025217275A2 (en) 2024-04-10 2025-10-16 Flagship Pioneering Innovations Vii, Llc Immune cell targeted compositions and related methods
WO2025229572A1 (en) 2024-05-01 2025-11-06 Glaxosmithkline Biologicals Sa Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
WO2025240680A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1084050A (en) * 1975-12-12 1980-08-19 Canadian D. A. Stuart Oil Co. Limited Acetals as enervatable surface-active organic compounds
US7514099B2 (en) 2005-02-14 2009-04-07 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
ATE536418T1 (en) 2004-06-07 2011-12-15 Protiva Biotherapeutics Inc LIPID ENCAPSULATED INTERFERENCE RNA
EP1781593B1 (en) 2004-06-07 2011-12-14 Protiva Biotherapeutics Inc. Cationic lipids and methods of use
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US8114636B2 (en) * 2006-02-10 2012-02-14 Life Technologies Corporation Labeling and detection of nucleic acids
CA2663083A1 (en) * 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
MX363224B (en) * 2006-10-03 2019-03-15 Alnylam Pharmaceuticals Inc Lipid containing formulations.
CA2689042A1 (en) 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
CA3044134A1 (en) 2008-01-02 2009-07-09 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
US20090263407A1 (en) 2008-04-16 2009-10-22 Abbott Laboratories Cationic Lipids and Uses Thereof
AU2009298802A1 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
WO2010042877A1 (en) 2008-10-09 2010-04-15 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
WO2011000106A1 (en) * 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
EP2525781A1 (en) * 2010-01-22 2012-11-28 Schering Corporation Novel cationic lipids for oligonucleotide delivery
US20110250641A1 (en) * 2010-04-08 2011-10-13 Matthew Jacob Powell Zwitterionic acid-labile surfactants and methods of use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150322433A1 (en) * 2012-12-20 2015-11-12 Sirna Therapeutics, Inc. POST-SYNTHETIC ORTHOGANAL AMIDATION PLUS METAL CATALYZED AZIDE-ALKYNE CYCLOADDITION CLICK CHEMISTRY ON siRNA
US10550385B2 (en) * 2012-12-20 2020-02-04 Sirna Therapeutics, Inc. Post-synthetic orthogonal amidation plus metal catalyzed azide-alkyne cycloaddition click chemistry on siRNA

Also Published As

Publication number Publication date
US9441228B2 (en) 2016-09-13
US20150211008A1 (en) 2015-07-30
EP2526113B1 (en) 2016-08-10
US20130053572A1 (en) 2013-02-28
US20130116419A1 (en) 2013-05-09
EP2526113A4 (en) 2013-11-27
EP2526113A1 (en) 2012-11-28
WO2011090965A1 (en) 2011-07-28
US9670487B2 (en) 2017-06-06
EP2525781A1 (en) 2012-11-28

Similar Documents

Publication Publication Date Title
US9441228B2 (en) Post-synthetic chemical modification of RNA at the 2′-position of the ribose ring via “click” chemistry
US20080213891A1 (en) RNAi Agents Comprising Universal Nucleobases
US9914745B2 (en) Morpholino-based antisense agent
JP2004500330A (en) Guanidinium-functionalized oligomers and their preparation
US10385090B2 (en) Nucleotide derivative or salt thereof, nucleotide-derived 5′-phosphate ester or salt thereof, nucleotide-derived 3′-phosphoramidite compound or salt thereof, and polynucleotide
FR2959228A1 (en) NUCLEOTIDES MODIFIED
US10844376B2 (en) Structurally-enhanced miRNA inhibitor S-TuD
Horie et al. Facile synthesis and fundamental properties of an N-methylguanidine-bridged nucleic acid (GuNA [NMe])
WO2011090968A1 (en) Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
Winkler et al. 2′‐O‐Lysylaminohexyl Oligonucleotides: Modifications for Antisense and siRNA
US20150322433A1 (en) POST-SYNTHETIC ORTHOGANAL AMIDATION PLUS METAL CATALYZED AZIDE-ALKYNE CYCLOADDITION CLICK CHEMISTRY ON siRNA
HK1257846A1 (en) Process for preparing phosphate compound bearing isotope
Kajino et al. (S)-5′-C-Aminopropyl-2′-O-methyl nucleosides enhance antisense activity in cultured cells and binding affinity to complementary single-stranded RNA
US12012432B2 (en) Nucleic acid complex, method for forming nucleic acid hybridization, pharmaceutical composition, nucleic acid probe, and complementary-strand nucleic acid complex
Albaneze-Walker et al. Synthesis of Phosphorodiamidate Oligonucleotide Dimers
Sato et al. Synthesis and characterization of novel (S)-5′-C-aminopropyl-2′-fluorouridine modified oligonucleotides as therapeutic siRNAs
Belousoff et al. Binding of HIV-1 TAR mRNA to a peptide nucleic acid oligomer and its conjugates with metal-ion-binding multidentate ligands
WO2020204130A1 (en) Rna capping method, production method for modified rna, and modified rna
EP2616549A1 (en) Chemical modification of rna at the 2'-position of the ribose ring via aaa coupling
Taniguchi et al. Enhancement of TFO triplex formation by conjugation with pyrene via click chemistry
Matsubara et al. Synthesis of siRNAs incorporated with cationic peptides R8G7 and R8A7 and the effect of the modifications on siRNA properties
JP5424236B2 (en) Oligonucleotide derivative, oligonucleotide construct using oligonucleotide derivative, compound for synthesizing oligonucleotide derivative, and method for producing oligonucleotide derivative
Patrushev et al. New Zwitter-Ionic Oligonucleotides: Preparation and Complementary Binding
Wu et al. Synthesis of Site‐Specifically Phosphate‐Caged siRNAs
JP6621831B2 (en) Nucleoside derivatives and uses thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION